Innovations In Diagnostics: Next Generation Molecular and Point-of-Care Diagnostics Driving Personalized Healthcare : Market Research Report

Innovations In Diagnostics: Next Generation Molecular and Point-of-Care Diagnostics Driving Personalized Healthcare

Published: Sep. 1, 2006 - 126 Pages

Executive Summary: Introduction to diagnostics; Challenges and opportunities in diagnostic innovation; Molecular technology innovations; Innovation in infectious disease diagnostics; Personalized medicine; Point-of-care testing; Competitive landscape
Chapter 1 Introduction to diagnostics: Summary; Introduction; The global IVD market; Key IVD players; Overview of diagnostic technologies; Future trends
Chapter 2 Challenges and opportunities in diagnostic innovation: Summary; Introduction; A changing healthcare environment; Challenges & opportunities
Chapter 3 Molecular technology innovations: Summary; Introduction; IVD technologies
Chapter 4 Innovation in infectious disease diagnostics: Summary; Introduction; Emerging infections; Multiple detection of infectious agents; Future challenges
Chapter 5 Personalized medicine: Summary; Introduction; Pharmacogenomics; Oncology; Future challenges
Chapter 6 Point-of-care testing: Summary; Introduction; Blood glucose tests; Infectious diseases; Cardiac diagnostics; Bladder cancer rapid test; HIV home tests; Future challenges
Chapter 7 Competitive landscape: Summary; Introduction; Key mergers & acquisitions; Competitive landscape; Pharma companies with Dx divisions; MedTech companies with Dx divisions; Dx Specialists; Technology specialists
Chapter 8 Appendix: Index
List of Figures: Figure 1.1: IVD market segments, 2005; Figure 1.2: IVD market segments projected growth, 2004-2010; Figure 3.3: Orion Genomics’ Second Code technology; Figure 5.4: The healthcare model of the future: Personalized medicine; Figure 5.5: Breast cancer management in the future; Figure 5.6: From diagnostic market candidate to a product: Three development phases; Figure 5.7: Potential roles of genomics in cancer; Figure 7.8: New cancer marker launches; Figure 7.9: Gen-Probe leads US STD market, 2002-05; Figure 7.10: IMI product sales by business segment, 2005; Figure 7.11: IMI’s leading market position in consumer diagnostics
List of Tables: Table 1.1: Top 15 IVD companies, 2005; Table 2.2: Development costs and timeframes to produce a new IVD in the US, 2006; Table 5.3: Cancer markers used in Dx tests; Table 7.4: Pure-play diagnostic companies and ownership of IVD companies by medical device and pharmaceutical companies; Table 7.5: Roche Diagnostics sales, H1 2006; Table 7.6: Gen-Probe product sales, 2005

Abstract

The global diagnostics market is undergoing radical change; novel technologies driven by miniaturization and advances in genomics will enhance the role of diagnostics in the healthcare market, allowing more tests to be performed at the point-of-care and facilitating the shift towards personalized medicine. “Innovation in Diagnostics” examines the advances in the rapidly growing field of molecular technologies that are enabling personalized healthcare to move into mainstream medicine. New opportunities in infectious disease testing, molecular oncology and pharmacogenomics are explored in detail, enabling you to understand the forces that are driving in vitro diagnostics (IVDs) into centre stage of the healthcare arena. Understand the changing relationship between IVD companies and the pharmaceutical industry, assess the convergence of IVDs and medical imaging, and develop an understanding of new technologies that will influence diagnostic product development and drug development programs.

Key findings of the report:

Consolidation in the IVD industry is highlighted by the dominance of the leading 15 companies, which account for almost 90% of the global IVD market. Roche is the major player with a 20% market share.
Fewer than 10% of practising doctors have been educated in molecular medicine, thus adoption of molecular tests in clinical practice will demand training and educational materials from the IVD industry.
The full clinical potential of molecular diagnostics has yet to be realized. Clinical applications beyond the field of infectious disease testing will make this the fastest-growing market segment in the next decade.
IVD companies devote 35% of revenues to R&D, significantly more than the pharmaceutical industry, underlining the driving force of technology innovation which is forcing the pace of change among players in the industry .
Genotyping of known biomarkers will reduce drug toxicity problems and contribute to better dosing regimens, offering the potential for fewer drug withdrawals resulting from safety concerns.

Key questions answered in this report:

What will the IVD market be worth by the end of the decade?
Which market segments will drive IVD market growth?
Which new technologies will reach the market in the next 2-3 years?
How is technology innovation impacting the dynamics and ownership of the IVD industry?
What are the key challenges in gaining acceptance of new technologies by users, payers and regulators?
How is technology innovation facilitating the transition of personalized medicine into standard healthcare practice?
How will IVD technology developments impact labelling of existing and future drugs?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Innovations In Diagnostics: Next Generation Molecular and Point-of-Care Diagnostics Driving Personalized Healthcare

Table of Contents

Abstract